|
|
|
|
|
Highlights from the 2023 American Urological Association Annual Meeting |
|
|
|
|
|
|
| Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in a Large-Scale Real-World Dataset |
| Michael Leapman, MD, MHS |
| Although the prognostic significance of the Decipher genomic classifier has been established in the context of randomized clinical trials and institutional cohorts, less is known about the associations between Decipher testing and oncologic outcomes among patients treated in the real-world practice setting. In this real-world study conducted at the national scale, Decipher genomic classifier was independently associated with the risk of biochemical recurrence and metastasis among patients managed in contemporary practice. |
|
|
|
|
|
| Development of a Longitudinal Prostate Cancer Transcriptomic and Real-World Clinical Data Linkage |
| Michael Leapman, MD, MHS
|
| Genomic classifiers have been shown to be prognostic and impact clinical decision-making in retrospective studies. However, less is known about prognostic performance in the real-world clinical setting. Michael Leapman and colleagues developed a novel linkage between the Decipher prostate genomic classifier and real-world patient data in the United States across payors and sites of care. |
|
|
|
|
|
|
Prostate Cancer: Localized: Radiation Therapy
|
|
| Real-World Assessment of MRI Predictors of Rectal Complications Following Transperineal SpaceOAR® Hydrogel Insertion
|
| Jonathan Kam, BMed, BSci (Med)Hons, MD
|
| This real-world data suggests SpaceOAR® hydrogel insertion results in a much higher rectal wall infiltration rate than suggested by the PIVOTAL trial (6% in PIVOTAL trial vs. 41% in this cohort) and there is increasing evidence of complications with SpaceOAR® in the literature and this series.
|
|
|
|
|
|
|
Prostate Cancer: Advanced (Including Drug Therapy) II
|
|
| Rapid, Durable, and Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS |
| Fred Saad, MD, FRSC |
| Patients with mHSPC receiving darolutamide + ADT + docetaxel achieved rapid, durable, and deep PSA responses, correlating with improved overall survival and prolonged time to PSA progression vs placebo + ADT + docetaxel. These data support using PSA response as a prognostic indicator of clinical outcomes in patients with mHSPC. |
|
|
|
|
|
|
|
|
|
|
| Efficacy and Safety of Darolutamide in Combination With ADT Therapy and Docetaxel in the North American Population From ARASENS |
| Neal D. Shore, MD, FACS |
| In North American patients with mHSPC, the addition of darolutamide to ADT + docetaxel led to a clinically meaningful reduction in risk of death by 41% and improved the key patient-relevant secondary endpoint of time to CRPC. The North American subgroup analysis of the primary endpoint was planned, whereas the secondary endpoint analyses were post hoc analyses. |
|
|
|
|
|
| Characteristics and Outcomes of Patients with Advanced Prostate Cancer Treated with Relugolix: A Single Center Experience
|
| Parth Shah
|
| Parth Shah presents the results of a single center analysis evaluating the characteristics and outcomes of patients with advanced prostate cancer treated with relugolix. The objective of this study was to evaluate the characteristics and cardiovascular outcomes of prostate cancer patients treated with relugolix at a single institution.
|
|
|
|
|
|
| Real-World Study on Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients Using a Urology Network in the USA (DEAR Study) |
| Neal Shore, MD, FACS |
| Neal Shore presented the results of DEAR, a real-world study on darolutamide, enzalutamide, and apalutamide for nmCRPC patients using a United States-based urology network. In this interim analysis of the DEAR study, despite similar baseline characteristics, fewer darolutamide patients discontinued treatment or progressed to mCRPC compared with patients treated with enzalutamide or apalutamide.
|
|
|
|
|
|
| PSA Response and Time-to-Castration Resistance among Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide, Enzalutamide, or Abiraterone |
| Benjamin H. Lowentritt, MD, FACS |
| This is among the first observational studies to describe real-world PSA responses and progression to castration resistance in mCSPC patients treated with ARSIs in US community urology practices. While differential PSA responses and time-to-castration resistance were observed among patients across the 3 drug groups, future studies that adjust for baseline patient differences/confounders are needed to ascertain these preliminary results. |
|
|
|
|
|
|
